SK Biopharmaceuticals, under the leadership of CEO Donghoon Lee, unveiled a significant milestone on August 18th by entering a technology export (L/O) agreement with 'Hikma MENA FZE'. This agreement paves the way for the commercialization of the groundbreaking epilepsy drug 'Cenobamate' across the Middle East and North Africa (MENA) region.

A spokesperson for the company expressed, "Through this strategic collaboration, we are poised to establish a formidable presence within the MENA market and offer novel therapeutic avenues to epilepsy patients across the region." The spokesperson elaborated, "The agreement encompasses an initial payment of $3 million coupled with subsequent royalties determined by sales figures."

Beyond the comprehensive regional arrangement for Cenobamate, SK Biopharma and Hikma have also solidified a strategic partnership that extends beyond the transactional dimension. A pivotal facet of this partnership involves SK Biopharma granting Hikma the prerogative of first negotiation for any upcoming product launches targeted at the MENA region.

According to company statements, this partnership not only optimizes the MENA market's potential but also includes a substantial upfront payment of $20 million, supplementing the fees associated with the Cenobamate agreement. The funds procured from this collaboration will be channeled towards amplifying research and development (R&D) efforts as well as facilitating strategic inorganic investments.

Hikma MENA FZE, a local subsidiary responsible for MENA sales, operates under the overarching umbrella of Hikma, a global pharmaceutical powerhouse with a footprint spanning the United States, Europe, the Middle East, and Africa. Hikma has emerged as a prominent player in the Middle East's pharmaceutical landscape, boasting robust market leadership and an extensive sales network throughout the MENA region.

Through the Hikma alliance, Cenobamate is slated to be available across 16 nations within the MENA territory, encompassing nations such as Saudi Arabia, the United Arab Emirates (UAE), and Egypt. Notably, the epilepsy market within the MENA region garnered a valuation of $442 million (equivalent to 59 billion won) in the year 2019.